GM2A and Parkinson disease: Concerning the identified progression‐related targets, ALKBH3, GLO1, IDO1, SERPINA3, SORD, TPST1, GM2A, MICB, SH3BGRL3, and TGFBI, we found them to be significantly associated with cognitive decline in the plasma of PD patients.